Glucagon (19-29) | CAS#64790-15-4 | pancreatic islet regulator

MedKoo Cat#: 597979 | Name: Glucagon (19-29)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Glucagon (19-29) is a novel regulator of the pancreatic islet physiology.

Chemical Structure

Glucagon (19-29)

CAS#64790-15-4

Theoretical Analysis

MedKoo Cat#: 597979

Name: Glucagon (19-29)

CAS#: 64790-15-4

Chemical Formula: C61H89N15O18S

Exact Mass: 1351.6231

Molecular Weight: 1352.53

Elemental Analysis: C 54.17; H, 6.63; N, 15.53; O, 21.29; S, 2.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Glucagon (19-29); Des(1-18) glucagon; Miniglucagon;

IUPAC/Chemical Name

(2S,5S,8S,11S,14S,17S,20S,23S,26S)-14-((1H-indol-3-yl)methyl)-26-((S)-5-amino-2-((S)-2-aminopropanamido)-5-oxopentanamido)-5-(2-amino-2-oxoethyl)-17-(3-amino-3-oxopropyl)-23-benzyl-2-((R)-1-hydroxyethyl)-11-isobutyl-20-isopropyl-8-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaoctacosanedioic acid

InChi Key

SVHJFTNFNMWDBS-FPLSMPAJSA-N

InChi Code

InChI=1S/C61H89N15O18S/c1-29(2)23-40(55(87)68-39(21-22-95-7)54(86)73-43(26-47(65)80)59(91)76-50(32(6)77)61(93)94)70-56(88)42(25-34-28-66-36-16-12-11-15-35(34)36)72-53(85)38(18-20-46(64)79)69-60(92)49(30(3)4)75-58(90)41(24-33-13-9-8-10-14-33)71-57(89)44(27-48(81)82)74-52(84)37(17-19-45(63)78)67-51(83)31(5)62/h8-16,28-32,37-44,49-50,66,77H,17-27,62H2,1-7H3,(H2,63,78)(H2,64,79)(H2,65,80)(H,67,83)(H,68,87)(H,69,92)(H,70,88)(H,71,89)(H,72,85)(H,73,86)(H,74,84)(H,75,90)(H,76,91)(H,81,82)(H,93,94)/t31-,32+,37-,38-,39-,40-,41-,42-,43-,44-,49-,50-/m0/s1

SMILES Code

C[C@@H](O)[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCSC)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,352.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lotersztajn S, Pavoine C, Brechler V, Roche B, Dufour M, Le-Nguyen D, Bataille D, Pecker F. Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins. J Biol Chem. 1990 Jun 15;265(17):9876-80. PubMed PMID: 2141022. 2: Bataille D, Dalle S. The forgotten members of the glucagon family. Diabetes Res Clin Pract. 2014 Oct;106(1):1-10. doi: 10.1016/j.diabres.2014.06.010. Epub 2014 Jul 3. Review. PubMed PMID: 25115338. 3: Pavoine C, Brechler V, Kervran A, Blache P, Le-Nguyen D, Laurent S, Bataille D, Pecker F. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9. PubMed PMID: 1852111. 4: Dalle S, Fontés G, Lajoix AD, LeBrigand L, Gross R, Ribes G, Dufour M, Barry L, LeNguyen D, Bataille D. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12. PubMed PMID: 11812748. 5: Authier F, Cameron PH, Merlen C, Kouach M, Briand G. Endosomal proteolysis of glucagon at neutral pH generates the bioactive degradation product miniglucagon-(19-29). Endocrinology. 2003 Dec;144(12):5353-64. Epub 2003 Aug 28. PubMed PMID: 12959981. 6: Dalle S, Smith P, Blache P, Le-Nguyen D, Le Brigand L, Bergeron F, Ashcroft FM, Bataille D. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76. PubMed PMID: 10196164. 7: Carrey EA, Epand RM. Conformational and biological properties of glucagon fragments containing residues 1-17 and 19-29. Int J Pept Protein Res. 1983 Sep;22(3):362-70. PubMed PMID: 6313539. 8: Blache P, Kervran A, Le-Nguyen D, Bataille D. Miniglucagon production from glucagon: an extracellular processing of a hormone used as a prohormone. Biochimie. 1994;76(3-4):295-9. Review. PubMed PMID: 7819338. 9: Green AK, Cobbold PH, Dixon CJ. Effects on the hepatocyte [Ca2+]i oscillator of inhibition of the plasma membrane Ca2+ pump by carboxyeosin or glucagon-(19-29). Cell Calcium. 1997 Aug;22(2):99-109. PubMed PMID: 9292228. 10: Brimble KS, Ananthanarayanan VS. Calcium binding and translocation properties of glucagon and its fragments. Biochemistry. 1993 Feb 16;32(6):1632-40. PubMed PMID: 8431443. 11: Sauvadet A, Pecker F, Pavoine C. Inhibition of the sarcolemmal Ca2+ pump in embryonic chick heart cells by mini-glucagon. Cell Calcium. 1995 Jul;18(1):76-85. PubMed PMID: 7585885. 12: Blache P, Kervran A, Le-Nguyen D, Dufour M, Cohen-Solal A, Duckworth W, Bataille D. Endopeptidase from rat liver membranes, which generates miniglucagon from glucagon. J Biol Chem. 1993 Oct 15;268(29):21748-53. PubMed PMID: 8408029. 13: Ferguson EC. QUESTION 1: Can mini-glucagon be used to manage hypoglycaemia as an outpatient? Arch Dis Child. 2016 May;101(5):497-9. doi: 10.1136/archdischild-2015-309202. Review. PubMed PMID: 27095113. 14: Sauvadet A, Rohn T, Pecker F, Pavoine C. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Res. 1996 Jan;78(1):102-9. PubMed PMID: 8603492. 15: Sauvadet A, Rohn T, Pecker F, Pavoine C. Arachidonic acid drives mini-glucagon action in cardiac cells. J Biol Chem. 1997 May 9;272(19):12437-45. PubMed PMID: 9139691. 16: Fontés G, Lajoix AD, Bergeron F, Cadel S, Prat A, Foulon T, Gross R, Dalle S, Le-Nguyen D, Tribillac F, Bataille D. Miniglucagon (MG)-generating endopeptidase, which processes glucagon into MG, is composed of N-arginine dibasic convertase and aminopeptidase B. Endocrinology. 2005 Feb;146(2):702-12. Epub 2004 Nov 11. PubMed PMID: 15539558. 17: Hanawa H, Watanabe R, Hayashi M, Yoshida T, Abe S, Komura S, Liu H, Elnaggar R, Chang H, Okura Y, Kato K, Kodama M, Maruyama H, Miyazaki J, Aizawa Y. A novel method to assay proteins in blood plasma after intravenous injection of plasmid DNA. Tohoku J Exp Med. 2004 Mar;202(3):155-61. PubMed PMID: 15065641. 18: Lefèbvre PJ. The intriguing diversity of the glucagon gene products. Curr Diab Rep. 2002 Jun;2(3):201-2. PubMed PMID: 12643173. 19: Dalle S, Blache P, Le-Nguyen D, Le Brigand L, Bataille D. Miniglucagon: a local regulator of islet physiology. Ann N Y Acad Sci. 1998 Dec 11;865:132-40. PubMed PMID: 9928005. 20: Bataille D, Fontés G, Costes S, Longuet C, Dalle S. [Miniglucagon: is the precursor a traitor to its family or a genius? ]. Journ Annu Diabetol Hotel Dieu. 2004:139-49. Review. French. PubMed PMID: 15259312.